Sandbox/01

	WikiDoc Resources for Sandbox/01
Articles
Most recent articles on Sandbox/01 Most cited articles on Sandbox/01 Review articles on Sandbox/01 Articles on Sandbox/01 in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Sandbox/01 Images of Sandbox/01 Photos of Sandbox/01 Podcasts & MP3s on Sandbox/01 Videos on Sandbox/01
Evidence Based Medicine
Cochrane Collaboration on Sandbox/01 Bandolier on Sandbox/01 TRIP on Sandbox/01
Clinical Trials
Ongoing Trials on Sandbox/01 at Clinical Trials.gov Trial results on Sandbox/01 Clinical Trials on Sandbox/01 at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Sandbox/01 NICE Guidance on Sandbox/01 NHS PRODIGY Guidance FDA on Sandbox/01 CDC on Sandbox/01
Books
Books on Sandbox/01
News
Sandbox/01 in the news Be alerted to news on Sandbox/01 News trends on Sandbox/01
Commentary
Blogs on Sandbox/01
Definitions
Definitions of Sandbox/01
Patient Resources / Community
Patient resources on Sandbox/01 Discussion groups on Sandbox/01 Patient Handouts on Sandbox/01 Directions to Hospitals Treating Sandbox/01 Risk calculators and risk factors for Sandbox/01
Healthcare Provider Resources
Symptoms of Sandbox/01 Causes & Risk Factors for Sandbox/01 Diagnostic studies for Sandbox/01 Treatment of Sandbox/01
Continuing Medical Education (CME)
CME Programs on Sandbox/01
International
Sandbox/01 en Espanol Sandbox/01 en Francais
Business
Sandbox/01 in the Marketplace Patents on Sandbox/01
Experimental / Informatics
List of terms related to Sandbox/01

Template:DiseaseDisorder infobox

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Overview

Porphyria cutanea tarda (PCT) is the most common subtype of porphyria. The disorder results from low levels of the enzyme responsible for the fifth step in heme production. Heme is a vital molecule for all of the body's organs. It is a component of hemoglobin, the molecule that carries oxygen in the blood.

Presentation

When signs and symptoms occur, they usually begin in adulthood and result from the skin becoming overly sensitive to sunlight. Areas of skin exposed to the sun develop severe blistering, scarring, changes in pigmentation, and increased hair growth. Exposed skin becomes fragile and is easily damaged. People with porphyria cutanea tarda also have increased iron levels in the liver. They face a higher risk of developing abnormal liver function and liver cancer.^[1]

Causes

In the acquired form, the signs and symptoms of this condition are triggered by non genetic factors such as alcohol abuse, excess iron, certain hormones, and viral infections. However, in the inherited form of the disease, which affects up to 20% of PCT patients, the condition arises from a mutation in the uroporphyrinogen decarboxylase gene, although environmental and chemical factors may trigger or exacerbate symptoms.
Drug side effect: Chlorpropamide, Tolbutamide, Tolazamide

Diagnosis

Physical Examination

Skin

Extremities

Porphyria cutanea tarda. With permission from Dermatology Atlas.^[2]
Porphyria cutanea tarda. With permission from Dermatology Atlas.^[2]
Porphyria cutanea tarda. With permission from Dermatology Atlas.^[2]
Porphyria cutanea tarda. With permission from Dermatology Atlas.^[2]
Porphyria cutanea tarda. With permission from Dermatology Atlas.^[2]
Porphyria cutanea tarda. With permission from Dermatology Atlas.^[2]
Porphyria cutanea tarda. With permission from Dermatology Atlas.^[2]
Porphyria cutanea tarda. With permission from Dermatology Atlas.^[2]
Porphyria cutanea tarda. With permission from Dermatology Atlas.^[2]
Porphyria cutanea tarda. With permission from Dermatology Atlas.^[2]
Porphyria cutanea tarda. With permission from Dermatology Atlas.^[2]
Porphyria cutanea tarda. With permission from Dermatology Atlas.^[2]
Porphyria cutanea tarda. With permission from Dermatology Atlas.^[2]

Face

Porphyria cutanea tarda. With permission from Dermatology Atlas.^[2]

Epidemiology

This type of porphyria occurs in an estimated 1 in 25,000 people, including both inherited and sporadic (noninherited) cases. An estimated 80 % of porphyria cutanea tarda cases are sporadic. The exact frequency is not clear because many people with the condition never experience symptoms.

Genetics

Inherited mutations in the UROD gene cause about 20 % of cases (the other 80 % of cases do not have mutations in UROD, and are classified as sporadic). UROD makes an enzyme called uroporphyrinogen III decarboxylase, which is critical to the chemical process that leads to heme production. The activity of this enzyme is usually reduced by 50 % in all tissues in people with the inherited form of the condition.

Nongenetic factors such as alcohol abuse, excess iron, and others listed above can increase the demand for heme and the enzymes required to make heme. The combination of this increased demand and reduced activity of uroporphyrinogen decarboxylase disrupts heme production and allows byproducts of the process to accumulate in the body, triggering the signs and symptoms of porphyria cutanea tarda.

The HFE gene makes a protein that helps cells regulate the absorption of iron from the digestive tract and into the cells of the body. Certain mutations in the HFE gene cause hemochromatosis (an iron overload disorder). People who have these mutations are also at an increased risk of developing porphyria cutanea tarda.

In the 20% of cases where porphyria cutanea tarda is inherited, it is inherited in an autosomal dominant pattern, which means one copy of the altered gene is sufficient to decrease enzyme activity and cause the signs and symptoms of the disorder.

20% of cases of porphyria cutanea tarda are inherited in an autosomal dominant pattern.

Treatment

Chloroquine and venesection can be part of a management strategy.^[3]

Cultural references

Porphyria Cutanea Tarda is also the name of a song by the punk band AFI on their album Black Sails in the Sunset.

References

↑ Fracanzani AL, Taioli E, Sampietro M, Fatta E, Bertelli C, Fiorelli G, Fargion S (2001). "Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease". J Hepatol. 35 (4): 498–503. PMID 11682034.
↑ ^2.00 ^2.01 ^2.02 ^2.03 ^2.04 ^2.05 ^2.06 ^2.07 ^2.08 ^2.09 ^2.10 ^2.11 ^2.12 ^2.13 "Dermatology Atlas".
↑ Sarkany RP (2001). "The management of porphyria cutanea tarda". Clin Exp Dermatol. 26 (3): 225–32. PMID 11422163.

Additional Resources

Kauppinen R (2005). "Porphyrias". Lancet. 365 (9455): 241–52. PMID 15652607.
Lecha M, Herrero C, Ozalla D (2003). "Diagnosis and treatment of the hepatic porphyrias". Dermatol Ther. 16 (1): 65–72. PMID 12919129.
Nordmann Y, Puy H (2002). "Human hereditary hepatic porphyrias". Clin Chim Acta. 325 (1–2): 17–37. PMID 12367763.
Sassa S (2002). "The porphyrias". Photodermatol Photoimmunol Photomed. 18 (2): 56–67. PMID 12147038.
"Porphyria Cutanea Tarda" Porphyria South Africa, University of Cape Town/Groote Schurr Hospital

Template:Vesiculobullous disease Template:Endocrine, nutritional and metabolic pathology Template:SIB

de:Porphyria cutanea tarda nl:Porphyria cutanea tarda sr:Касна кожна порфирија

Template:WikiDoc Sources

[1] Fracanzani AL, Taioli E, Sampietro M, Fatta E, Bertelli C, Fiorelli G, Fargion S (2001). "Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease". J Hepatol. 35 (4): 498–503. PMID 11682034.

[Dermatology_Atlas-2] 2.00 ^2.01 ^2.02 ^2.03 ^2.04 ^2.05 ^2.06 ^2.07 ^2.08 ^2.09 ^2.10 ^2.11 ^2.12 ^2.13 "Dermatology Atlas".

[3] Sarkany RP (2001). "The management of porphyria cutanea tarda". Clin Exp Dermatol. 26 (3): 225–32. PMID 11422163.

[1]

[2]

[3]